Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34053084&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Alpha-defensins: risk factor for thrombosis in COVID-19 infection #MMPMID34053084
Abdeen S; Bdeir K; Abu-Fanne R; Maraga E; Higazi M; Khurram N; Feldman M; Deshpande C; Litzky LA; Heyman SN; Montone KT; Cines DB; Higazi AA
Br J Haematol 2021[Jul]; 194 (1): 44-52 PMID34053084show ga
The inflammatory response to SARS/CoV-2 (COVID-19) infection may contribute to the risk of thromboembolic complications. alpha-Defensins, antimicrobial peptides released from activated neutrophils, are anti-fibrinolytic and prothrombotic in vitro and in mouse models. In this prospective study of 176 patients with COVID-19 infection, we found that plasma levels of alpha-defensins were elevated, tracked with disease progression/mortality or resolution and with plasma levels of interleukin-6 (IL-6) and D-dimers. Immunohistochemistry revealed intense deposition of alpha-defensins in lung vasculature and thrombi. IL-6 stimulated the release of alpha-defensins from neutrophils, thereby accelerating coagulation and inhibiting fibrinolysis in human blood, imitating the coagulation pattern in COVID-19 patients. The procoagulant effect of IL-6 was inhibited by colchicine, which blocks neutrophil degranulation. These studies describe a link between inflammation and the risk of thromboembolism, and they identify a potential new approach to mitigate this risk in patients with COVID-19 and potentially in other inflammatory prothrombotic conditions.
free
free
free
Br+J+Haematol 2021 ; 194 (1): 44-52
